Evidence map›Paper›PMID 28967897›Full record

ArticleBone marrow transplantation2017

Donor T-cell responses and disease progression patterns of multiple myeloma.

M Eefting, L C de Wreede, P A Von dem Borne, C J M Halkes, S Kersting, E W A Marijt, H Putter, H Veelken, J Schetelig, J H F Falkenburg

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

M EeftingDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
L C de WreedeDepartment of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.
P A Von dem BorneDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
C J M HalkesDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
S KerstingDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
E W A MarijtDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
H PutterDepartment of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.
H VeelkenDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
J ScheteligMedical Department I, University Hospital Carl Gustav Carus, Technische Universität Dresden & DKMS, German Bone Marrow Donor Center, Dresden, Germany.
J H F FalkenburgDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Donor T-cells transferred after allogeneic stem cell transplantation (alloSCT) can result in long-term disease control in myeloma by the graft-versus-myeloma (GvM) effect. However, T-cell therapy may show differential effectiveness against bone marrow (BM) infiltration and focal myeloma lesions resulting in different control and progression patterns. Outcomes of 43 myeloma patients who underwent T-cell-depleted alloSCT with scheduled donor lymphocyte infusion (DLI) were analyzed with respect to diffuse BM infiltration and focal progression. For comparison, 12 patients for whom a donor search was started but no alloSCT was performed, were analyzed. After DLI, complete disappearance of myeloma cells in BM occurred in 86% of evaluable patients. The probabilities of BM progression-free survival (PFS) at 2 years after start of donor search, alloSCT and DLI, were 17% (95% confidence interval 0-38%), 51% (36-66%), and 62% (44-80%) respectively. In contrast, the probabilities of focal PFS at 2 years after start of donor search, alloSCT and DLI, were 17% (0-38%), 30% (17-44%) and 28% (11-44%), respectively. Donor-derived T-cell responses effectively reduce BM infiltration, but not focal progression in myeloma, illustrating potent immunological responses in BM with only limited effect of T-cells on focal lesions.

Indexed as

AdultBone MarrowDisease ProgressionFemaleHematopoietic Stem Cell TransplantationHumansLymphocyte DepletionLymphocyte TransfusionMaleMiddle AgedMultiple MyelomaTissue DonorsT-Lymphocytes

Identifiers

PMID28967897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.